anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In an expanded consultation group is being conducted in the study group on the importance of primary prevention of cardiovascular diseases and on the reduction of cardiovascular risk by taking statins. Patients are given brochures and information materials on the risk factors for cardiovascular diseases and the possibility of their correction. Also, the patients of the study group are regularly reminded (2 times a month) with the help of SMS mailings and calls of health workers about the need to follow the doctor's recommendations for taking atorvastatin and returning to the medical institution.
BACKGROUND: The primary genetic risk factor for heritable pulmonary arterial hypertension is the presence of monoallelic mutations in the BMPR2 gene. The incomplete penetrance of BMPR2 mutations implies that additional triggers are necessary for pulmonary arterial hypertension occurrence. Pulmonary artery stenosis directly raises pulmonary artery pressure, and the redirection of blood flow to unobstructed arteries leads to endothelial dysfunction and vascular remodeling. We hypothesized that right pulmonary artery occlusion (RPAO) triggers pulmonary hypertension (PH) in rats with Bmpr2 mutations.
METHODS AND RESULTS: Male and female rats with a 71 bp monoallelic deletion in exon 1 of Bmpr2 and their wild-type siblings underwent acute and chronic RPAO. They were subjected to full high-fidelity hemodynamic characterization. We also examined how chronic RPAO can mimic the pulmonary gene expression pattern associated with installed PH in unobstructed territories. RPAO induced precapillary PH in male and female rats, both acutely and chronically. Bmpr2 mutant and male rats manifested more severe PH compared with their counterparts. Although wild-type rats adapted to RPAO, Bmpr2 mutant rats experienced heightened mortality. RPAO induced a decline in cardiac contractility index, particularly pronounced in male Bmpr2 rats. Chronic RPAO resulted in elevated pulmonary IL-6 (interleukin-6) expression and decreased Gdf2 expression (corrected P value<0.05 and log2 fold change>1). In this context, male rats expressed higher pulmonary levels of endothelin-1 and IL-6 than females.
CONCLUSIONS: Our novel 2-hit rat model presents a promising avenue to explore the adaptation of the right ventricle and pulmonary vasculature to PH, shedding light on pertinent sex- and gene-related effects.
The utility model discloses seed coating equipment which is mainly composed of a machine frame, a revolving kettle, a liquid material supply device, a powdery material supply device, a drying device, a discharge device, an electric control device, etc., wherein the powdery material supply device comprises a powder box and a conveyer. The powder box is provided with an electromagnetic vibration component, and the conveyor is a vibration conveyor. The discharge device is a vibration conveying chute provided with an upper layer of screen piece and a lower layer of screen piece. When the utility model works, the powdery materials can be uniformly supplied in the way of loosening. After the seed coating processing is finished, large particles, broken particles and powdery materials in the finished products can be removed while in discharge. Therefore, the utility model has the advantages of good quality, low cost and high productive efficiency. The utility model is not only suitable for seed coating processing but also is suitable for medicine coating processing and the foodstuff coating processing.
Chewing is one of the important steps in the process of food digestion, and it is crucial for human nutritional intake and oral health. Chewing efficiency relates to the ability to eat and is influenced by many factors, with the key factor being the absence of posterior teeth. According to traditional occlusal theory, the anterior teeth guide and act as a facade, while the posterior teeth provide support and chewing function. The loss of posterior teeth leads to a decrease in chewing efficiency. In 1954, Dr. A. Albert Yurkstas and others proposed that in healthy adults, the loss of the first molar results in a 33% decrease in chewing efficiency; the loss of the second and third molars results in a 44% decrease; and the loss of the first, second, and third molars results in a 78% decrease. This study laid the foundation for understanding how tooth loss leads to decreased chewing efficiency and highlights the goal of prosthodontics to restore dental arches and chewing function to benefit people.

The purpose of this experiment is to combine the study of chewing efficiency with the expertise of prosthodontics in reconstruction, aiming to investigate the impact of contemporary gold-standard artificial implant-supported fixed restorations on chewing efficiency. The study invites patients missing the second molar and those receiving implant-supported fixed prostheses reconstruction in the Department of Prosthodontics at National Taiwan University Hospital. The new and simpler color-changeable chewing gum will be used to test their chewing efficiency. This will explore the importance of implant-supported fixed prostheses in reconstructing chewing function after the loss of the second molar, aiming to improve patient well-being and understanding of dental implants by restoring chewing function through clinical implant reconstruction. In the research field, this study provides guidance for the reconstruction strategies of chewing function
Standard dose induction Visit 1 Day 1 (intake/baseline) Participants will commence induction with a dose of 4mg if COWS is above 7. If COWS is below 7, participant will be instructed to return the next day, so that COWS can be above 7 to start the study.
In addition to conventional physiotherapy, training will be given in the Hippotherapy Simulator for 15 minutes a day, 5 days a week for 4 weeks. The hippotherapy simulator serves a wide range of purposes from recreational use that mimics the movements of a real horse or can make similar movements, to fitness, exercise, sports, education and therapy and is suitable for use by individuals with cerebral palsy.
This study consisted of 16 visits (Screening, Baseline \[Day 0\], and 14 post-baseline assessment visits) that occurred at 4-week intervals through Week 56. Enrolled subjects were randomized 1:1 to receive ESBA1008 or EYLEA. All subjects received active intravitreal (IVT) injections at baseline with 2 additional loading doses of the assigned investigational product at 4-week intervals (ie, at Weeks 4 and 8) and then received further injections at 8-weeks intervals at Weeks 16, 24, and 32. Subjects in the ESBA1008 group also received an injection at Week 44, while subjects in the EYLEA group also received injections at Weeks 40 and 48. To maintain the study masking, subjects in the ESBA1008 group received sham injections at Weeks 40 and 48 (when the subjects in the EYLEA group received active injections), while subjects in the EYLEA group received a sham injection at Week 44 (when the subjects in the ESBA1008 group received an active injection). All subjects were followed up to Week 56. Week 40 visit was the end of assessment period for the 8-week treatment cycle.
Saxagliptin 

In a controlled clinical trial, once-daily, orally administered saxagliptin in healthy subjects at doses up to 400 mg daily for 2 weeks (80 times the MRHD) had no dose-related clinical adverse reactions and no clinically meaningful effect on QTc interval or heart rate. 

In the event of an overdose, appropriate supportive treatment should be initiated as dictated by the patient’s clinical status. Saxagliptin and its active metabolite are removed by hemodialysis (23% of dose over 4 hours). 

Metformin hydrochloride 

Overdose of metformin hydrochloride has occurred, including ingestion of amounts greater than 50 grams. Hypoglycemia was reported in approximately 10% of cases, but no causal association with metformin hydrochloride has been established. Lactic acidosis has been reported in approximately 32% of metformin overdose cases [see Warnings and Precautions (5.1)]. Metformin is dialyzable with a clearance of up to 170 mL/min under good hemodynamic conditions. Therefore, hemodialysis may be useful for removal of accumulated drug from patients in whom metformin overdosage is suspected.
INTRODUCTION: The role of neoadjuvant therapy (NAT) in the treatment of locally advanced rectal cancer (LARC) has been well proven, but its impact on patients who relapse remains unknown. This study aims to elucidate the influence of initial treatment and MRI-defined risk factors on postrecurrent survival in patients with LARC recurrence.
PATIENTS AND METHODS: LARC patients who underwent radical surgery and subsequently developed recurrence were retrospectively identified. Patients were stratified on the basis of MRI-defined local risk assessment and the initial treatment modality for the primary tumor (NAT or primary surgery). The patients were classified into four groups: high-risk LARC with NAT (HiN), high-risk LARC with primary surgery (HiS), low-risk LARC with NAT (LoN), and low-risk LARC with primary surgery (LoS). The primary endpoint was survival after recurrence.
RESULTS: A total of 381 patients who experienced relapse were identified from among 2329 LARC patients. Salvage surgery was performed on 33.1% of these patients. Patients who experienced single-site recurrence or who underwent salvage surgery exhibited significantly prolonged survival times after recurrence (P < 0.001). Patients in the HiS group had poorer survival after recurrence than those in the other three groups (P = 0.034). This subset of patients, characterized by receiving less adjuvant treatment after primary surgery, had a shorter recurrence interval than those in the other groups (P = 0.001).
CONCLUSIONS: Our findings reaffirm the prognostic significance of salvage surgery in patients from a LARC cohort who experienced relapse. Moreover, MRI-defined high-risk LARC patients who received upfront surgery without NAT had shorter intervals of recurrence and poorer survival outcomes after recurrence. Our results highlight the critical role of NAT in improving patient survival after recurrence.
TRIAL REGISTRATION: Supplementary registration was carried out at clinicaltrials.gov (Registration number: NCT06314737) on March 14, 2024. The study was retrospectively registered.
This study will utilize Simon's two-stage design: 16 patients will be enrolled in the first portion of this study. If 4 or more patients are progression-free at 12 weeks, an additional 16 patients will be enrolled for a total of n = 32 patients enrolled.
In the past decade, the US opioid crisis has emerged as a leading cause of death among adults. It has also led to an increase in invasive bacterial and fungal infections; and HIV and HCV outbreaks in multiple regions. Rural communities have had an especially disproportionate burden from the impact of opioid use disorder (OUD). Treatment of OUD with pharmacotherapy is one of the most effective strategies for reducing OUD-related mortality and morbidity. But while there has been increasing will for expanding pharmacotherapy, stigma - from community, providers and patients-remains a significant barrier to uptake pharmacotherapy and harm reduction. The approach to substance use has historically favored abstinence strategies that are often without evidence, influenced by punitive, stigmatizing framework. This stigma may be even more prevalent in rural communities. To date there have been very few effective interventions to address inter- and intrapersonal stigma, and none with sustained effectiveness. The investigators propose adapting and piloting a shared decision-making aid for patients presenting to the ED or are being admitted at two hospitals in rural Missouri, where there is a high prevalence of OUD and its complications. The decision-aid is an evidence-based intervention show to increase knowledge, engagement and decision-making concordant with patient values in a variety of medical conditions. It is feasible that by democratizing treatment and standardizing decision-making counseling, the decision aid can mediate attitudes and reduce stigma. The investigators hypothesize by delivering standardized, high-quality knowledge to both provider and patient, that stigma can be reduced in both parties. In Aim 1 the investigators will adapt an existing decision aid for OUD treatment to the specific context of rural hospital care. This decision aid will be a part of an existing bundled care program for OUD and related infections that the investigators have implemented in these hospitals. In Aim 2 the investigators will conduct a randomized pilot comparing the decision aid intervention with counseling as usual without decision aid to assess feasibility, acceptability and preliminary effectiveness for reducing stigma in substance use, HIV, OUD pharmacotherapy and harm reduction. The investigators will measure these around the time of the intervention and in longitudinal follow up. The findings could potentially identify a novel intervention and methodology for treatment expansion and stigma reduction that has not been previously explored, especially in the rural context, where need is high. Following the successful completion of this pilot trial, the investigators will develop an expanded multi-site comparative effectiveness trial of the decision aid, implementation studies, and cost-effectiveness analysis.
The invention relates to an active ingredient composition used in cosmetic products, said composition containing vegetable extracts and combating in particular free radicals. The active ingredient composition is an alcohol-based mixture of vegetable extracts that is devoid of liposomes, consisting of between 0.1 and 2 wt. % green coffee-bean extract, between 0.1 and 2 wt. % Camellia sinensis leaf extract, between 0.1 and 2 wt % Pongamia pinnata extract and between 0.1 and 2 wt. % Angelica archangelica root extract and a residual content of a monovalent C2-C5 alcohol to obtain the total of 100 wt. %. The free radical protection factor amounts to 1400-2900 x 10<14> free radicals per mg.
One of the most common cancers of the urinary tract is bladder tumors. Bladder cancers are divided into two groups: non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer. (1)  Trans-Peritoneal  Radical Cystectomy (RC) with  pelvic lymphadenectomy is the standard technique in muscle invasive and high risk non-muscle invasive bladder cancer (2). and Urologist around the world are more familiar with trans-peritoneal technique. In some articles extra-peritoneal Radical Cystectomy (RC) implied as an decreased  postoperative  complications techniques. In this letter we want to compare these two techniques and find out the pros and cons of these techniques.
Mechanical instrumentation in all groups continued with titanium Gracey curettes (8mm in diameter, Langer ½, item code: 7103, Kohler Medizintechnik, GmbH \& Co, Ltd, Stockach, Germany) until the clinician gently felt that the surface was sufficiently debrided.There is no laser application. The laser tip is placed in the peri-implant sulcus but not activated.
This is a randomized, placebo controlled, double blind study. 60 men and women over the age of 55 with indications of pre-diabetes will be recruited for participation and randomly assigned to one of four 12 week exercise training programs: 1)Supervised aerobic exercise 3 days per week followed by a carbohydrate drink along with daily oral administration of Metformin. 2) Supervised aerobic exercise 3 days per week followed by a protein drink along with daily oral administration of Metformin. 3) Supervised aerobic exercise 3 days per week followed by a carbohydrate drink along with daily oral administration of matching placebo. 4) Supervised aerobic exercise 3 days per week followed by a protein drink along with daily oral administration of placebo.

Daily administration of Metformin will begin as one 500 mg tablet for the first week and will increase by 500 mg/day/week until reaching 2000 mg/day by week 4 during a 12 week exercise training program. The titration dosing scheme and taking metformin/placebo with meals will help reduce the most common side effects (i.e.,gastrointestinal discomfort). If participants experience gastrointestinal discomfort, the dose will be lowered to 1500 mg/day.
Irritable Bowel Syndrome (IBS) and Ulcerative Colitis (UC) affect principally the gut, causing symptoms that alter intestinal motility, with a multifactorial etiology. The pharmacological and nutritional treatment varies according to the symptoms and activity of each patient. The most commonly used are the standard diet (SD), which excludes foods known as irritants or inflammatory. On the other hand, are the low fodmap diet (LFD) (fermentable oligosaccharides. disaccharides, monosaccharides and polyols), these highly fermentable carbohydrates can pass unabsorbed to the colon and induce the gas production due to the fermentation of gut microbiota and cause symptoms such as: bloating, flatulence, abdominal pain and altered bowel habit. It consists in two stages: first the restriction of all foods that contain fodmaps and second the re exposure in which indicate the introduction of each food restricted before to evaluate the tolerance, for 6 to 8 weeks. Some studies show that the low fodmap diet improve the symptoms in both groups, however because of the restriction and the limited content of foods, they have had risk to present nutritional deficiencies. The aim of the present is to evaluate the effect of a low fodmap diet for 10 weeks on gastrointestinal symptoms, nutritional status and microbiota in patients with IBS and UC.

Methods: a controlled, blinded clinical trial will be conducted in patients who assist to medical monitoring in gastroenterology service with diagnosis of IBS or UC. The sample size was determined with a 0.5 effect size, an alpha error 0.05 and power of 80%, which determined 64 patients for each group (total: 128). After singing the informed consent, will be determined their total energy expenditure (TEE) and consecutively will be assigned an ID previously randomized to SD (\<16 g of fodmaps) or LFD (\<10 g of fodmaps), with a distribution of 55% carbohydrates, 20% proteins and 25% lipids. During the 10 weeks will be three follow-ups, first the basal, intermediate (week 5) and final (10 weeks after), will be performed body composition (RJL Quantum III), anthropometry (waist, hip, arm and chest circumference), gastrointestinal symptoms (ROMA III and Mayo Scale), quality of life (WHOQL-BREF), food frequency and 24-hour reminder and blood chemistry (anemia, hypoalbuminemia, vitamin D, calcium, potassium, c reactive protein, VSG, etc), all of them basal and final.
Subjects will receive one oral dose of 40 mg omeprazole once a day for 6 days. On the 5th day, a single oral 160 mg dose of GED-0301 will be given together with omeprazole.
A video acquisition system for a narrow cavitary space based on a microprobe structure, comprising an intelligent computer aided diagnosis system and a microprobe (104). The intelligent computer aided diagnosis system trains a large number of pictures of different lesions using a deep learning technique, and can complete auxiliary diagnosis of different common lesions in the colonoscopy process. The microprobe (104) is provided at the tail end of a clamp channel (103) for taking samples from tissues. When the intelligent computer aided diagnosis system determines that some of the tissues taken out are pathological tissues, the microprobe (104) is retracted from the clamp channel (103) and carries the pathological tissues out of a colonoscope (102) duct from the clamp channel (103). When it is determined that the some of the tissues taken out are normal intestinal tissues or intestinal debris, the microprobe (104) discharges the tissues and is not retracted. The video acquisition system can reduce the probability of missed detection of lesions.
Cyclosporine Capsules USP MODIFIED have increased bioavailability compared to Sandimmune (Cyclosporine Capsules USP). The absolute bioavailability of cyclosporine administered as Sandimmune (Cyclosporine Capsules USP) is dependent on the patient population, estimated to be less than 10% in liver transplant patients and as great as 89% in some renal transplant patients. The absolute bioavailability of cyclosporine administered as Cyclosporine Capsules USP MODIFIED has not been determined in adults. In studies of renal transplant, rheumatoid arthritis and psoriasis patients, the mean cyclosporine AUC was approximately 20% to 50% greater and the peak blood cyclosporine concentration (Cmax) was approximately 40% to 106% greater following administration of Cyclosporine Capsules USP MODIFIED compared to following administration of Sandimmune (Cyclosporine Capsules USP). The dose normalized AUC in de novo liver transplant patients administered Cyclosporine Capsules USP MODIFIED 28 days after transplantation was 50% greater and Cmax was 90% greater than in those patients administered Sandimmune (Cyclosporine Capsules USP). AUC and Cmax are also increased (Cyclosporine Capsules USP MODIFIED relative to Sandimmune (Cyclosporine Capsules USP)) in heart transplant patients, but data are very limited. Although the AUC and Cmax values are higher on Cyclosporine Capsules USP MODIFIED relative to Sandimmune (Cyclosporine Capsules USP), the predose trough concentrations (dose-normalized) are similar for the two formulations.

Following oral administration of Cyclosporine Capsules USP MODIFIED, the time to peak blood cyclosporine concentrations (Tmax) ranged from 1.5 to 2.0 hours. The administration of food with Cyclosporine Capsules USP MODIFIED decreases the cyclosporine AUC and Cmax. A high fat meal (669 kcal, 45 grams fat) consumed within one-half hour before Cyclosporine Capsules USP MODIFIED administration decreased the AUC by 13% and Cmax by 33%. The effects of a low-fat meal (667 kcal, 15 grams fat) were similar.

The effect of T-tube diversion of bile on the absorption of cyclosporine from Cyclosporine Capsules USP MODIFIED was investigated in eleven de novo liver transplant patients. When the patients were administered Cyclosporine Capsules USP MODIFIED with and without T-tube diversion of bile, very little difference in absorption was observed, as measured by the change in maximal cyclosporine blood concentrations from pre-dose values with the T-tube closed relative to when it was open: 6.9 ± 41% (range 55% to 68%).
FIELD: medicine, pharmacology, phytotherapy. SUBSTANCE: invention relates to agents of vegetable origin exhibiting sedative, anti-inflammatory and capillary-strengthening effect. The proposed bath agent comprises medicinal plants: birch leaves and marjoram herb taken in the ratio = 1:1. The proposed agent can be prepared as granules and tablets and can be used as decoctions and infusions also. Carbon dioxide releasing in acid-basic interaction in the presence of water provides high biological availability of water- dissolved biologically active substances, stabilizes chemical composition, exhibits irritating effect on nerve endings in all cutaneous integument that results to the enhanced blood supply in cutaneous capillaries. Part of carbon dioxide penetrates through skin and enters in blood. Blood saturation with carbon dioxide exhibits strong irritating effect on inspiratory center and stimulates function of lung and bronchi. Also, kidney function and amount of excreted urine are alternated and metabolic processes in muscles and other organs are improved. EFFECT: enhanced effectiveness of agent, valuable medicinal properties. 5 cl, 16 tbl